📊 ZYME Key Takeaways
Is Zymeworks Inc. (ZYME) a Good Investment?
Zymeworks exhibits strong revenue growth (+38.9% YoY) with improving loss trends (EPS +33.3% YoY), but remains deeply unprofitable with -87.3% operating margins and negative free cash flow (-$34.5M). While the strong balance sheet ($268.5M equity, 0.00x D/E) provides runway, the company lacks a demonstrated path to profitability with losses consuming nearly 77 cents per dollar of revenue.
Why Buy Zymeworks Inc. Stock? ZYME Key Strengths
- Revenue growth of 38.9% YoY demonstrates top-line momentum
- Improving loss profile with diluted EPS loss shrinking 33.3% YoY
- Fortress balance sheet with $268.5M equity, no long-term debt, and 5.88x current ratio
ZYME Stock Risks: Zymeworks Inc. Investment Risks
- Operating losses of $92.5M against $106M revenue indicate severe unit economics
- Negative operating cash flow (-$33M) and free cash flow (-$34.5M) create ~15-month cash runway at current burn
- No gross margin data available; operating margin of -87.3% suggests R&D-heavy model without margin expansion evidence
Key Metrics to Watch
- Gross profit margin trend (critical missing data for pharma analysis)
- Operating cash flow inflection point to positive
- Revenue growth sustainability and cost structure rationalization
- Cash runway and timeline to break-even on operating basis
Zymeworks Inc. (ZYME) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 5.88x current ratio provides a solid financial cushion.
ZYME Profit Margin, ROE & Profitability Analysis
ZYME vs Healthcare Sector: How Zymeworks Inc. Compares
How Zymeworks Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Zymeworks Inc. Stock Overvalued? ZYME Valuation Analysis 2026
Based on fundamental analysis, Zymeworks Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Zymeworks Inc. Balance Sheet: ZYME Debt, Cash & Liquidity
ZYME Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Zymeworks Inc.'s revenue has declined by 74% over the 5-year period, indicating business contraction. The most recent EPS of $-1.72 indicates the company is currently unprofitable.
ZYME Revenue Growth, EPS Growth & YoY Performance
ZYME Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $16.0M | $2.3M | $-0.26 |
| Q2 2025 | $19.2M | $2.3M | $0.03 |
| Q1 2025 | $10.0M | -$22.6M | $-0.30 |
| Q3 2024 | $16.0M | -$24.4M | $-0.39 |
| Q2 2024 | $7.0M | -$24.4M | $-0.49 |
| Q1 2024 | $10.0M | -$24.4M | $-0.37 |
| Q3 2023 | $2.6M | -$24.4M | $-0.41 |
| Q2 2023 | $5.4M | -$24.4M | $-0.76 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Zymeworks Inc. Dividends, Buybacks & Capital Allocation
ZYME SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Zymeworks Inc. (CIK: 0001937653)
📋 Recent SEC Filings
❓ Frequently Asked Questions about ZYME
What is the AI rating for ZYME?
Zymeworks Inc. (ZYME) has an AI rating of SELL with 72% confidence, based on fundamental analysis of SEC EDGAR filings.
What are ZYME's key strengths?
Claude: Revenue growth of 38.9% YoY demonstrates top-line momentum. Improving loss profile with diluted EPS loss shrinking 33.3% YoY.
What are the risks of investing in ZYME?
Claude: Operating losses of $92.5M against $106M revenue indicate severe unit economics. Negative operating cash flow (-$33M) and free cash flow (-$34.5M) create ~15-month cash runway at current burn.
What is ZYME's revenue and growth?
Zymeworks Inc. reported revenue of $106.0M.
Does ZYME pay dividends?
Zymeworks Inc. does not currently pay dividends.
Where can I find ZYME SEC filings?
Official SEC filings for Zymeworks Inc. (CIK: 0001937653) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is ZYME's EPS?
Zymeworks Inc. has a diluted EPS of $-1.08.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is ZYME a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Zymeworks Inc. has a SELL rating with 72% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is ZYME stock overvalued or undervalued?
Valuation metrics for ZYME: ROE of -30.2% (sector avg: 15%), net margin of -76.6% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy ZYME stock in 2026?
Our dual AI analysis gives Zymeworks Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is ZYME's free cash flow?
Zymeworks Inc.'s operating cash flow is $-33.0M, with capital expenditures of $1.5M. FCF margin is -32.6%.
How does ZYME compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -76.6% (avg: 12%), ROE -30.2% (avg: 15%), current ratio 5.88 (avg: 2).